Capricor Therapeutics Faces PDUFA Date: What Investors Should Know
Capricor's stock dropped nearly 8% as it awaits an FDA decision on Deramiocel for Duchenne muscular dystrophy.
Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger
Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million privat…
TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz
TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by…
Werewolf Therapeutics and Ambros Therapeutics Join Forces: Implications for Oncology Investors
A strategic merger between Werewolf and Ambros Therapeutics aims to enhance oncology therapeutics, r…
Bunker Hill Mining and Silver47 Merge: A New Force in North American Silver and Critical Minerals
Bunker Hill Mining and Silver47 have merged in a $163M all-stock deal, positioning themselves as lea…
Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology
Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and in…
Ultragenyx's GENGLYCOS Approval: A Game Changer for Rare Disease Therapies
Ultragenyx's recent FDA approval for GENGLYCOS signals a significant shift in rare disease treatment…
Motorola Solutions Expands into Counter-Drone Technology: Key Takeaways from the $1.5 Billion Acquisition
Motorola Solutions' $1.5 billion acquisition of D-Fend Solutions positions the company at the forefr…
Ultragenyx Pharma's Surge: FDA Approval for GENGLYCOS and Its Market Implications
Ultragenyx Pharma's shares jumped ~14% following FDA approval for GENGLYCOS, highlighting its potent…
Moderna's Landmark Phase 3 Win: What It Means for MRNA and the Biotech Sector
Moderna's recent Phase 3 trial success has sent shockwaves through the biotech sector, propelling it…